These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 32702809

  • 21. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
    Tao HY, He F, Shi QY, Liu R, Wang ZL, Du KP, Li JF, Liu H, Lu ZQ, Zhang JJ, Bai YH.
    Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
    [Abstract] [Full Text] [Related]

  • 22. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW.
    Ann Oncol; 2018 Sep 01; 29(9):1972-1979. PubMed ID: 30016391
    [Abstract] [Full Text] [Related]

  • 23. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z, Mao YP, Tang J, Lan XW, OuYang PY, Xie FY.
    Tumour Biol; 2016 Apr 01; 37(4):4429-38. PubMed ID: 26499947
    [Abstract] [Full Text] [Related]

  • 24. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q, Lu L, Wang X, Lin Y, Chen Y, Chen H, Chen S, Lin S, Zhang Y, Zheng P, Chen X.
    Am J Otolaryngol; 2022 Apr 01; 43(1):103193. PubMed ID: 34509080
    [Abstract] [Full Text] [Related]

  • 25. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
    Li Y, Chen QY, Tang LQ, Liu LT, Guo SS, Guo L, Mo HY, Chen MY, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Shao JY, Sun Y, Tan J, Chen S, Ma J, Zhao C, Mai HQ.
    BMC Cancer; 2017 Aug 24; 17(1):567. PubMed ID: 28836950
    [Abstract] [Full Text] [Related]

  • 26. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
    Liang YJ, Wen DX, Luo MJ, Tang LQ, Guo SS, Wang P, Chen QY, Liu LT, Mai HQ.
    Eur J Cancer; 2021 Dec 24; 159():133-143. PubMed ID: 34743068
    [Abstract] [Full Text] [Related]

  • 27. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Zhang WW, Lin JY, Wang GY, Huang CL, Tang LL, Mao YP, Zhou GQ, Liu LZ, Tian L, Li JB, Ma J, Guo R.
    Radiother Oncol; 2024 May 24; 194():110189. PubMed ID: 38432309
    [Abstract] [Full Text] [Related]

  • 28. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Mu X, Liu H, Wu J, Chen S, Peng X, Wang J, Wei Z, He L, Liu J, Lu Z, Su Y.
    Aging (Albany NY); 2022 Aug 26; 14(16):6727-6739. PubMed ID: 36036759
    [Abstract] [Full Text] [Related]

  • 29. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH, Zhou XY, Pan YG, Chen S, Ye ZH, Chen GD.
    Cancer Med; 2020 Feb 26; 9(4):1287-1297. PubMed ID: 31859464
    [Abstract] [Full Text] [Related]

  • 30. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
    Wang L, Wu Z, Xie D, Lv S, Xia L, Su Y.
    Radiat Oncol; 2020 Jul 02; 15(1):160. PubMed ID: 32615984
    [Abstract] [Full Text] [Related]

  • 31. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
    You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, Li CF, Zou X, Yu T, Cao JY, Zhang MX, Jiang R, Sun R, Mo HY, Guo L, Cao KJ, Lin AH, Sun Y, Qian CN, Ma J, Chen MY.
    Theranostics; 2017 Jul 02; 7(8):2314-2324. PubMed ID: 28740554
    [Abstract] [Full Text] [Related]

  • 32. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
    Li Y, Tang LQ, Liu LT, Guo SS, Liang YJ, Sun XS, Tang QN, Bei JX, Tan J, Chen S, Ma J, Zhao C, Chen QY, Mai HQ.
    Cancer Res Treat; 2018 Oct 02; 50(4):1304-1315. PubMed ID: 29334605
    [Abstract] [Full Text] [Related]

  • 33. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.
    Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J.
    Eur J Cancer; 2017 Apr 02; 75():150-158. PubMed ID: 28235726
    [Abstract] [Full Text] [Related]

  • 34. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B, Hu Y, Xiong RH, Pan YF, Xu QL, Kong XY, Cai R, Chen QQ, Tang HY, Jiang W.
    Oncotarget; 2017 Feb 21; 8(8):14078-14088. PubMed ID: 27845907
    [Abstract] [Full Text] [Related]

  • 35. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
    Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ.
    J Natl Cancer Inst; 2011 Dec 07; 103(23):1761-70. PubMed ID: 22056739
    [Abstract] [Full Text] [Related]

  • 36. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
    Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J.
    Ann Oncol; 2015 Jan 07; 26(1):205-211. PubMed ID: 25355717
    [Abstract] [Full Text] [Related]

  • 37. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
    Tang SQ, Xu C, Wang XS, Tang LL, Li WF, Chen L, Mao YP, Guo R, Liu Q, Sun Y, Ma J.
    Oral Oncol; 2020 Jun 07; 105():104686. PubMed ID: 32283514
    [Abstract] [Full Text] [Related]

  • 38. Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma.
    Yu YF, Zhou P, Zhou R, Lin Q, Wu SG.
    Ann Med; 2024 Dec 07; 56(1):2383959. PubMed ID: 39086168
    [Abstract] [Full Text] [Related]

  • 39. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y, Ma J.
    JAMA; 2022 Aug 23; 328(8):728-736. PubMed ID: 35997729
    [Abstract] [Full Text] [Related]

  • 40. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J, Sun Y.
    Int J Cancer; 2019 Jul 01; 145(1):295-305. PubMed ID: 30613964
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.